Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.45 |
| ▸ | PPARG | P37231 | 12/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14219122 | 0.87 | PPARA (0.47) | PPARAPPARGL3MBTL1 | |
| SCHEMBL3600282 | 0.87 | PPARA (0.46) | PPARAPPARGL3MBTL1ALDH1A1 | |
| SCHEMBL13547014 | 0.85 | PPARA (0.47) | PPARAPPARGL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL3609694 | 0.81 | PPARA (0.55) | PPARAPPARGL3MBTL1TSHR | |
| SCHEMBL3619631 | 0.79 | DGAT1 (0.48) | PPARAPPARGL3MBTL1 | |
| SCHEMBL3615928 | 0.79 | PPARG (0.40) | PPARAPPARGL3MBTL1ALDH1A1TSHR | |
| SCHEMBL3604902 | 0.78 | PPARA (0.49) | PPARAPPARGL3MBTL1ALDH1A1TSHR | |
| SCHEMBL3613267 | 0.76 | PPARA (0.48) | PPARAPPARGL3MBTL1CYP2C9KCNH2 | |
| SCHEMBL3618601 | 0.76 | ALDH1A1 (0.48) | PPARAPPARGALDH1A1TSHRNPSR1 | |
| SCHEMBL3612881 | 0.76 | PPARA (0.54) | PPARAPPARGL3MBTL1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| EP-2104671-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | Mutabilis SA (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008038136-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | MUTABILIS SA (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | CBR1, OXER1, CBR3 | PPARA 2162/4885PPARG 1817/4885L3MBTL1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.